Leyla Asadova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Leyla Asadova has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Canan Eroğlu Güneş
Department of Medical Biology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
1 shared publication - Ercan Kurar
Department of Medical Biology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
1 shared publication - Sedef Akçaalan
Department of Medical Biology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
1 shared publication
Latest Publications
- 29 October 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (12) , 1-9
Anticancer potential of chamaejasmenin B: apoptotic and antioxidant effects on pancreatic cancer cells
The aim of this study was to investigate the effect of Chamaejasmenin B (CHB), a phytochemical, on human pancreatic cancer cell line (MIA PaCa-2). CCK-8 test was performed to evaluate the cytotoxic effect of CHB. To elucidate the molecular mechanism of CHB, expression levels of important genes in the cell cycle and apoptosis pathways were evaluated by qPCR and Western blot analysis. In addition, the effects of CHB on the colony formation capacity of cells, total oxidant and total antioxidant levels were also evaluated. The IC50 dose of CHB on MIA PaCa-2 cells was found as 647 µM at 48 h. After CHB treatment in MIA PaCa-2 cells, expressions of BAX, CASP3, CASP7, CYCS, FADD, FAS, CCND2 and P53 genes were significantly increased. However, a decrease in the expressions of CDK4, CDK6, CCND1 and CCND3 genes was observed. In addition, an elevation in CASP3 and P53 protein levels and a decrease in the level of CCND1 protein were determined. CHB treatment significantly suppressed the colony formation capacity in MIA PaCa-2 cells. In addition to these, an increase in total antioxidant levels was observed. These findings suggest that CHB seems to be a promising anticancer therapeutic agent in the treatment of pancreatic cancer.
- 29 October 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (12) , 1-9
Anticancer potential of chamaejasmenin B: apoptotic and antioxidant effects on pancreatic cancer cells
The aim of this study was to investigate the effect of Chamaejasmenin B (CHB), a phytochemical, on human pancreatic cancer cell line (MIA PaCa-2). CCK-8 test was performed to evaluate the cytotoxic effect of CHB. To elucidate the molecular mechanism of CHB, expression levels of important genes in the cell cycle and apoptosis pathways were evaluated by qPCR and Western blot analysis. In addition, the effects of CHB on the colony formation capacity of cells, total oxidant and total antioxidant levels were also evaluated. The IC50 dose of CHB on MIA PaCa-2 cells was found as 647 µM at 48 h. After CHB treatment in MIA PaCa-2 cells, expressions of BAX, CASP3, CASP7, CYCS, FADD, FAS, CCND2 and P53 genes were significantly increased. However, a decrease in the expressions of CDK4, CDK6, CCND1 and CCND3 genes was observed. In addition, an elevation in CASP3 and P53 protein levels and a decrease in the level of CCND1 protein were determined. CHB treatment significantly suppressed the colony formation capacity in MIA PaCa-2 cells. In addition to these, an increase in total antioxidant levels was observed. These findings suggest that CHB seems to be a promising anticancer therapeutic agent in the treatment of pancreatic cancer.